- Maze Therapeutics (NASDAQ:MAZE) shares rose over 45% premarket on Thursday after the biopharmaceutical company announced an oversubscribed private placement of its securities to raise gross proceeds of approximately $150.0 million.
- The offering includes 4,000,002 shares at $16.25 each, a premium to the